The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
Sarepta has also entered into an agreement with Arrowhead to transfer 2,660,989 shares of Arrowhead common stock in satisfaction of $50 million of the company’s previously announced $100 million milestone payment obligation
SynerK owns intellectual property rights of SNK-2726, which is currently in the IND filing preparation stage
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
Deal includes DTx-1252, a potential therapy for the neuromuscular disorder Charcot-Marie-Tooth disease type 1A (CMT1A), and two additional preclinical programs for other neuroscience indications
DST-backed researchers from Pune demonstrate targeted gene-silencing approach that significantly inhibits tumor growth with minimal toxicity
The Cambridge hub is designed to expand Zealand Pharma’s global research capabilities
Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
Subscribe To Our Newsletter & Stay Updated
